CBOT HOLDINGS INC

Form 425

October 17, 2006

Filed by Chicago Mercantile Exchange Holdings Inc. pursuant

to Rule 425 under the Securities Act of 1933, as amended, and

deemed filed pursuant to Rule 14a-12 under the Securities

Exchange Act of 1934, as amended.

Subject Company: CBOT Holdings, Inc.

Subject Company s Commission File No.: 001-32650

Investor Presentation October 17, 2006

*

^{*} Name effective upon transaction closing.

Discussion of Forward-Looking Statements
Statements
in
this
news
release
that
are
not

are
forward-looking
statements.
These
statements
are
not
guarantees
of
future
performance
and
involve
risks,
uncertainties
and
assumptions
that
are
difficult
to
predict.
Therefore,
actual
outcomes
and
results
may differ
materially
from
what
is
expressed
or
implied
in
any
forward-looking
statements.
Among
the
factors
that
might
affect
our
performance

historical facts

are: increasing competition by foreign and domestic competitors, including new entrants into our markets; our ability to keep pace with rapid technological developments, including our ability complete the development and implementation of the enhanced functionality required by our customers; our ability continue introducing competitive new

products and services

on a timely, cost-effective basis, including through our electronic trading capabilities, and our ability maintain the competitiveness of our existing products and services; our ability to adjust our fixed costs and expenses if our revenues decline; our ability to continue to realize the benefits of our transaction

processing services

provided to third parties; our ability to maintain existing customers and attract new ones; our ability to expand and offer our products in foreign jurisdictions; changes in domestic and foreign regulations; changes in government policy, including policies relating to common or directed clearing; the costs associated with protecting

our

intellectual

property rights and our ability to operate our business without violating the intellectual property rights of others; our ability to generate revenue from our market data that may be reduced eliminated by the growth of electronic trading; changes in our rate per

contract due to shifts in the mix

of

the

products

traded,

the

trading

venue

and

the

mix

of

customers

(whether

the

customer

receives

member

or

non-member

fees

or

participates

in

one

of

our

various

incentive

programs)

and

the

impact

of

our

tiered

pricing

structure;

the

ability

of

our

financial

safeguards

package

to

adequately

protect

us

from

the

credit risk of our clearing firms; changes in price levels and volatility in the derivatives markets and in underlying fixed income, equity, foreign exchange and commodities markets; economic, political and market conditions; our ability accommodate increases in trading volume without failure or degradation of performance

of our systems; our

ability to execute our growth strategy and maintain our growth effectively; our ability to manage the risks and control the costs associated with our acquisition, investment and alliance strategy; industry and customer consolidation; decreases in trading and clearing activity; the imposition of transaction tax on futures

and options on

futures transactions; and seasonality of the derivatives business. More detailed information about factors that may affect our performance may be found in our press release for the merger and our filings with the Securities and Exchange Commission, including our most recent Quarterly Report on Form

10-Q, which is

available

in

the

Investor

Information

section

of

the

CME

Web

site.

We

undertake

no

obligation

to

publicly

update

any

forward-looking

statements,

whether

as

a

result

of

new

information,

future

events

or

otherwise.

Additional Information

This material is not a substitute for the prospectus/proxy statement and any other documents CME and CBOT intend to file wi and Exchange Commission (SEC). Investors and security holders are urged to read such prospectus/proxy statement and any of documents, when available, which will contain important information about the proposed transaction. The prospectus/proxy statement and any of documents, when available, which will contain important information about the proposed transaction. The prospectus/proxy statement and any of documents filed or to be filed by CME and CBOT with the SEC are or will be, available free of charge at the SEC (www.sec.gov) or from CME by directing a request to CME, 20 South Wacker Drive, Chicago, IL 60606, Attention: Sharehold from CBOT by directing a request to 141 West Jackson Boulevard, Chicago, IL 60604, Attention: Investor Relations.

CME, CBOT and their respective directors, executive officers and

other employees may be deemed to be participants in the solicitation of

proxies from the security holders of CME or CBOT in connection with the proposed transaction. Information about CME s dexecutive officers is available in CME s proxy statement, dated March 10, 2006, for its 2006 annual meeting of stockholders, about CBOT s directors and executive officers is available in CBOT s proxy statement, dated March 29, 2006, for its 2006 an shareholders. Additional information about the interests of potential participants will be included in the prospectus/proxy state becomes available. This document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor s any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qual the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

NOTE:

Unless

otherwise

noted, all references to **CME** volume, open interest and rate per contract information in the text of this document exclude CME s non-traditional **TRAKRS** products, for which **CME** receives significantly lower clearing fees of less than one cent per contract on average, as well as **CME**

Auction Markets products. SM

2 Landmark Transaction
Combination will establish the world s largest derivatives exchange and provide significant value to CME s and CBOT s customers and shareholders

Solidifies combined company s status as the premier global exchange

Expands presence in attractive derivatives markets

Positions combined company for continued growth

Creates operational and cost efficiencies for customers

\$125+ million in estimated annual cost savings expected to be achieved year two post closing

Expected to be accretive to earnings 12 18 months post close

Potential revenue opportunities

Enhances operating leverage Strategically Attractive Financially Compelling

Transaction Summary
Accretive to earnings 12 18 months after the closing
Expected Accretion:
Terrence A. Duffy, Chairman; Charles P. Carey, Vice-Chairman;
Craig S. Donohue, CEO; Bernard W. Dan, Special Advisor
Management:
CME and CBOT members
existing core trading rights will be
preserved

Core Rights:

For each CBOT share, shareholders will receive 0.3006 CME shares, or they may elect Cash with value equal to 0.3006 CME shares based on the ten-day average CME closing price ending 2 days prior to close (subject to proration based on a maximum of \$3 billion of cash)

Consideration Mix:

Mid-2007 (subject to regulatory, shareholder and CBOT

member approvals)

Anticipated Closing:

\$240 million

Reciprocal Break-Up Fee:

\$151.28 per share

(1)

Price Per Share:

29 Directors to include 20 Directors from CME and 9 Directors

from CBOT

Board of Directors:

CME Shareholders: minimum of 69% (based on elections)

CBOT Shareholders: up to 31% (based on elections)

Pro Forma Ownership: Aggregate Consideration:

\$8.0 billion

(1) Based on CME s closing price of \$503.25 on October 16, 2006

5
CME and CBOT Shareholder Benefits
Well-Positioned
in Dynamic
Global Industry
Stronger Base
to Build Core
Derivatives
Business
Accretive
Transaction

Platform for

Product

Innovation and

Growth

Substantial

Benefits

Transaction expected to create value for shareholders of

both companies

Synergy

Opportunities

Significant User

Benefits

```
6
Well-Positioned in Dynamic Global Industry
Largest market capitalization among global exchange
participants
NOTE: Market data as of 10/16/06, and market capitalization based on diluted share counts.
1.
Assumes all stock transaction.
2.
Adjusted to reflect cash component of transaction on a pro rata basis.
$0
$5
$10
$15
$20
$25
$30
```

Pro Forma

Market Capitalization
CME/CBOT
NYX/NXT
DB
ICE/NYBOT
LSE
NDAQ
TSX
ISE
(1)
(2)
\$24.8
\$19.9
\$16.0
\$5.4
\$5.0
\$5.0
\$2.9
\$1.9
\$7.1
\$10.0
\$0.8
\$17.7
\$9.9

Market Capitalization (\$ billions)

\$4.6

7
Foreign
Exchange
10%
Eurodollars
29%
Equities
27%
Commodity

& Other 8% 30-Year **Bonds** 5% 10-Year Notes 12% 5-Year Notes 5% 2-Year Notes 2% Other Interest Rates 2% Equities 39% Eurodollars 44% Commodities & Other 2% Foreign Exchange 15% Platform for Product Innovation and Growth Strong and broad platform with a diversified product mix NOTE: Data as of 1H06. Commodities & Other 20% 10-Year Notes 37% 30-Year **Bonds** 13% Other Interest Rates 6% 2-Year Notes 4%

5-Year Notes

15% Equities

5%

CME Standalone

Transaction Revenue Mix

CBOT Standalone

Transaction Revenue Mix

Pro Forma

Transaction Revenue Mix

```
8
0
300
600
900
1,200
1,500
```

Stronger Base to Build Core Derivatives Business The combined company would be the leading global derivatives exchange based on trading volume, listing three of the four most actively traded futures contracts in the world

Source: FIA.

NOTE: Volume figures do not include options on futures.

2005 Futures Volume (contracts in millions) 2005 Top Futures Exchanges 1,444 561 785 344 188 167 116 108 99 70 62 883 CME/CBOT Eurex Euronext .liffe Bolsa de Mercadorias & **Futuros** Nymex Mexican Derivatives Exchange Dalian Commodity Exchange London Metal Exchange National Stock Exchange of India Tokyo Commodity Exchange #1 CME Eurodollar Futures CBOT 10-year Treasury Note Futures CME E-mini S&P 500 Index Futures

9 CME and CBOT customers will benefit from increased scale, liquidity, product diversification and functionality Significant User Benefits Creates operational and cost efficiencies for market users

Access to distinct products and services on an integrated platform

Broad pipeline of innovative new products and

functionality

Efficiencies through integrated systems and combined open-auction trading environment

Seamless continuation of current clearing services, which secures existing margin benefits for customers

10

Historic CME/CBOT clearing agreement announced in April 2003 and fully operational in January 2004

Integration executed successfully and ahead of schedule

Worked with two exchanges, all 80 clearing firms and BOTCC

Substantial savings for our clearing firms and their customers

\$1.6 billion decrease in performance bonds for users

\$200 million decrease in security deposits for clearing firms

Combined risk capital pool and generated other operational efficiencies

Proven Experience Delivering Synergies

11

Technology

Related

50%

Trading Floor

/ Operations

15%

Administrative

35%

Substantial Potential Cost Savings

Expected cost savings of \$125+ million annually,

beginning in year two post close

Cost Savings Areas

Total: \$125+ million

12
Potential Revenue Opportunities
CBOT and CME combined will be well-positioned to generate incremental revenue
Global Expansion
OTC Initiatives

Leverage CME and CBOT s

global product suite, user base and relationships

JADE

Electronic trading of Ags

Build on distinct product suites to grow market share in OTC markets:

Swapstream

Clearing360

FXMarketSpace Cross-Selling

Cross-sell the distinct product suite to the customer base of both companies New Products

Create efficiencies of spread products and product extensions in

Interest rate derivatives

Agricultural commodities

Enhanced product innovation CME/CBOT

13

Strong Financial Profile

1. Pro

forma

figures

adjusted

tο

eliminate

clearing

fee

revenue

paid

from

CBOT

to

CME.

2. Operating Income and Net Income is unadjusted for incremental transaction-related expense, and amortization of identifiab Expected to be accretive to earnings 12-18 months post

closing \$778 \$903 (2) LTM Pro Forma as of 6/30/2006 (\$ Millions) **CME** Standalone **CBOT** Standalone Pro Forma All Stock Pro Forma All Stock **Cost Savings** \$0 \$125 Revenue (1) \$1,026 \$532 \$1,490 \$1,490 Operating Income \$584 \$194 % Margin 57% 37% 52% 61% Net Income (2) \$355 \$116 \$471 \$546 % Margin 35% 22%32%

37%

14 CBOT Overview 0 700 1,400 2,100 2,800 3,500 2001 2002 2003 2004

2005

2006 YTD (through Sept.) 3,191 1,033 Average Daily Volume (contracts in thousands)

Established in 1848, a leading futures and futures-options exchange

More than 50 different futures and options products traded by open auction and electronically

Strong market position and scalable business platform

Global reach and focused international education efforts driving organic growth of core products

Established strategic alliances JADE 50/50 joint venture Hosting agreements with regional North American grain exchanges 2001-2006 CAGR 25%

15 CBOT Financial Profile

Proven track record 2000 through 2005 CAGR
ADV 24%
Revenue 17%
Expense 8%
0
700
1,400
2,100

2,800 3,500 0% 10% 20% 30% 40% 50% 2001 2002 2003 2004 2005 1H06 Operating Leverage ADV in thousands Operating margin 19% 5% 31% 20%

28% 44%

16 Roadmap to Completion

File S-4 with SEC

CBOT and CME shareholder and CBOT member approvals

Regulatory approvals
The transaction is anticipated to close mid-2007

17 Transaction Highlights

Solidifies combined company s status as the premier global exchange

Expands presence in attractive derivatives markets

Positions combined company for continued growth

Creates operational and cost efficiencies for customers

\$125+ million in estimated annual cost savings expected to be achieved year two post closing

Expected to be accretive to earnings 12 18 months post close

Potential revenue opportunities

Enhances operating leverage Strategically Attractive Financially Compelling